Here are the images. The early assays (ie in 2022) were OK but poor comparted to LTR, KDR, PLS and PMT at the same stage. In 2023 the results from another target do compare well with these 4 stocks. AZS is not yet at this stage but at AZS current development it compares much more favourably with WR1 but AZS is much riskier than WR1 as at April 2023.
1. June 22
July 22
October 22
The following are from January to April 23 - they show much better lengths than early assays (at a different prospect).